

Anti-VZV ELISA (IgA)















Test instruction

ORDER NO.	ANTIBODIES AGAINST	IG CLASS	SUBSTRATE	FORMAT
EI 2650-9601 A	VZV (Varicella zoster virus)	IgA	Ag-coated microplate wells	96 x 01 (96)

Indication: Varicella zoster virus infection.

Principle of the test: The ELISA test kit provides a semiquantitative in vitro assay for human antibodies of the IgA class against varicella zoster viruses (VZV) in serum or plasma. The test kit contains micro-titer strips each with 8 break-off reagent wells coated with VZV antigens. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgA antibodies (also IgG and IgM) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgA (enzyme conjugate) catalysing a colour reaction.

Contents of the test kit:

Component	Colour	Format	Symbol
1. Microplate wells coated with antigens: 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	
2. Calibrator (IgA, human), ready for use	dark red	1 x 2.0 ml	
3. Positive control (IgA, human), ready for use	blue	1 x 2.0 ml	
4. Negative control (IgA, human), ready for use	green	1 x 2.0 ml	
5. Enzyme conjugate peroxidase-labelled anti-human IgA (rabbit), ready for use	orange	1 x 12 ml	
6. Sample buffer ready for use	light blue	1 x 100 ml	
7. Wash buffer 10x concentrate	colourless	1 x 100 ml	
8. Chromogen/substrate solution TMB/H ₂ O ₂ , ready for use	colourless	1 x 12 ml	
9. Stop solution 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	
10. Test instruction	---	1 booklet	
11. Quality control certificate	---	1 protocol	
 Lot description			 Storage temperature
 In vitro determination			 Unopened usable until

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents must be disposed of in accordance with local disposal regulations.



Preparation and stability of the reagents

Note: All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below.

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bag).
Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for 4 months.
- **Calibrator and controls:** Ready for use. The reagents must be mixed thoroughly before use.
- **Enzyme conjugate:** Ready for use. The enzyme conjugate must be mixed thoroughly before use.
- **Sample buffer:** Ready for use.
- **Wash buffer:** The wash buffer is a 10x concentrate. If crystallisation occurs in the concentrated buffer, warm it to 37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionised or distilled water (1 part reagent plus 9 parts distilled water).
For example: For 1 microplate strip, 5 ml concentrate plus 45 ml water.
The working strength wash buffer is stable for 4 weeks when stored at +2°C to +8°C and handled properly.
- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light ☼. The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.
- **Stop solution:** Ready for use.

Warning: The controls used have tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2 using enzyme immunoassays and indirect immunofluorescence methods. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the agent sodium azide in a non-declarable concentration. Avoid skin contact.

Preparation and stability of the patient samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Sample dilution: Patient samples to be investigated are diluted **1:101** in sample buffer. For example: Add 10 µl serum to 1.0 ml sample buffer and mix well by vortexing (sample pipettes are not suitable for mixing).

NOTE: The calibrator and controls are prediluted and ready for use, do not dilute them.



Incubation

(Partly) manual test performance

Sample incubation: (1st step) Transfer 100 µl of the calibrator, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol. Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing: Manual: Empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.
Automatic: Wash reagent wells 3 times with 450 µl working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Modus").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Note: Residual liquid (> 10 µl) remaining in the reagent wells after washing can interfere with the substrate and lead to false low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short residence times) can lead to false high extinction values.

Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation: (2nd step) Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgA) into each of the microplate wells. Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing: Wash as described above.

Substrate incubation: (3rd step) Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature (+18°C to +25°C), protect from direct sunlight.

Stopping: Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement: **Photometric measurement** of the colour intensity should be made at a **wavelength of 450 nm** and a reference wavelength between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the microplate to ensure a homogeneous distribution of the solution.

Test performance using fully automated analysis devices

Sample dilution and test performance are carried out fully automatically using an analysis device. The incubation conditions programmed in the respective software authorised by EUROIMMUN may deviate slightly from the specifications given in the ELISA test instruction. However, these conditions were validated in respect of the combination of the EUROIMMUN Analyzer I, Analyzer I-2P or the DSX from Dynex and this EUROIMMUN ELISA. Validation documents are available on enquiry.

Automated test performance using other fully automated, open system analysis devices is possible. However, the combination should be validated by the user.



Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	C	P 6	P 14	P 22								
B	pos.	P 7	P 15	P 23								
C	neg.	P 8	P 16	P 24								
D	P 1	P 9	P 17									
E	P 2	P 10	P 18									
F	P 3	P 11	P 19									
G	P 4	P 12	P 20									
H	P 5	P 13	P 21									

The above pipetting protocol is an example of the **semiquantitative analysis** of antibodies in 24 patient samples (P 1 to P 24).

Calibrator (C), positive (pos.) and negative (neg.) control as well as the patient samples have been incubated in one well each. The reliability of the ELISA test can be improved by duplicate determinations of each sample.

The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimises reagent wastage.

Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

Calculation of results

The extinction value of the calibrator defines the upper limit of the reference range of non-infected persons (**cut-off**) recommended by EUROIMMUN. Values above the indicated cut-off are to be considered as positive, those below as negative.

Semiquantitative: Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of calibrator. Calculate the ratio according to the following formula:

$$\frac{\text{Extinction of the control or patient sample}}{\text{Extinction of calibrator}} = \text{Ratio}$$

EUROIMMUN recommends interpreting results as follows:

Ratio <0.8:	negative
Ratio ≥0.8 to <1.1:	borderline
Ratio ≥1.1:	positive

Evaluation information: For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another the sample should be retested.

For the interpretation of borderline results an investigation using further tests (e.g. avidity determination of antibody class IgG) can be helpful. Diagnosis can be secured by the determination of the titer change in two serum samples taken at an interval of at least 7 days and analysed in parallel.

For diagnosis, the clinical symptoms of the patient should always be taken into account along with the serological results.



Test characteristics

Calibration: As no international reference serum exists for the detection of IgA class antibodies against VZV, results are provided in the form of ratios which are a relative measure of the concentration of antibodies.

For every group of tests performed, the extinction values of the calibrator and the ratios of the positive and negative controls must lie within the limits stated for the relevant test kit lot. A quality control certificate containing these reference values is included. If the values specified for the controls are not achieved, the test results may be inaccurate and the test should be repeated.

The activity of the enzyme used is temperature-dependent and the extinction values may vary if a thermostat is not used. The higher the room temperature during the incubation steps, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrators are subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

Antigen: The antigen used are highly purified VZV proteins (strain "Ellen") from infected, human fibroblasts (NHDF).

Detection limit: The lower detection limit is defined as the mean value of an analyte-free sample plus three times the standard deviation and is the smallest detectable antibody titer. The detection limit of the Anti-VZV ELISA (IgA) is ratio 0.08.

Cross reactivity: The quality of the antigen used ensures a high specificity of the ELISA. Sera from patients with infections caused by various agents were investigated with the EUROIMMUN Anti-VZV ELISA (IgA).

Antibodies against	n	Anti-VZV ELISA (IgA)
Adenovirus	10	0%
Bordetella pertussis PT	10	0%
Bordetella FHA	10	0%
Brucella abortus	8	0%
Chlamydia pneumoniae	10	0%
Chlamydia trachomatis	10	0%
EBV-CA	10	0%
Helicobacter pylori	10	0%
HSV Pool	10	0%
Influenza virus A	10	0%
Influenza virus B	10	0%
Legionella pneumoniae	10	0%
Mycoplasma pneumoniae	10	0%
Parainfluenza virus Pool	10	0%
RSV	10	0%
Toxoplasma gondii	10	0%
Yersinia enterocolitica	10	0%

Interference: Haemolytic, lipaemic and icteric samples showed no influence on the result up to a concentration of 10 mg/ml for haemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation (CV) using 3 sera. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed in 6 different test runs.



<i>Intra-assay variation, n = 20</i>		
Serum	Mean value (Ratio)	CV (%)
1	2.4	3.7
2	3.2	3.8
3	6.3	2.3

<i>Inter-assay variation, n = 4 x 6</i>		
Serum	Mean value (Ratio)	CV (%)
1	2.6	4.6
2	3.5	4.3
3	6.7	4.6

Specificity and sensitivity: A cohort of 12 clinically characterised patient samples (interlaboratory test samples from INSTAND) was examined using the EUROIMMUN ELISA. The test shows a specificity of 100% and a sensitivity of 100%.

n = 12		INSTAND	
		positive	negative
ELISA	positive	2	0
	negative	0	10

Reference range: The levels of anti-VZV antibodies (IgA) were analysed with this EUROIMMUN ELISA in a panel of 500 healthy blood donors. With a cut-off of ratio 1.0, 21.2% of the blood donors were anti-VZV positive (IgA).

Clinical significance

Varicella zoster virus (VZV), synonyme: human herpes virus 3 (HHV3), is the causative agent of chickenpox (varicella) after which it establishes latency and can subsequently reactivate to cause herpes zoster (shingles) [1, 2]. The virus is strictly human [3]. Chickenpox - a very contagious disease - has traditionally been regarded as a benign, inevitable disease among children (25% in 1-4-year-olds, 43% in 5-8-year-olds, 27% in 9-18-year-olds) with typical blister-like rash of the entire skin [1, 4, 5]. Now we know varicella can also be a serious infection, even in childhood, but especially in young and older adults and during pregnancy [6, 7, 8, 9].

Zoster is the endogenous recurrence of an earlier varicella infection or the result of a reinfection with existing residual immunity [2]. The average incidence of herpes zoster in Europe is 3 per 1000 people per year in the total population and more than 10 per 1000 people per year in those aged >80 years [10]. The entire virus genome is present in the latently infected ganglia. VZV is latent in multiple ganglia along the entire human neuraxis [1]. In zoster, the rash affects the spreading area of one or several sensitive nerve roots, especially T3-L3 and N. trigeminus [2, 3]. Central nervous system (CNS) complications can follow both primary infection and reactivation of VZV [8, 11]. The more serious manifestations arise when VZV invades the spinal cord or cerebral arteries after reactivation of the virus, causing diseases such as myelitis, focal vasculopathies, and encephalitis [7, 11].

Varicella also causes serious infections during pregnancy with severe consequences of maternal varicella for the infant [6, 12, 13]. At birth, maternal infection with the VZV poses a truly life-threatening risk to the newborn. The neonatal mortality rate is up to 20-30%, if the maternal VZV-infection occurs between day 4 ante partum and day 2 post partum [14]. Patients with congenital varicella syndrome (CVS) typically show clinical symptoms such as skin lesions, neurological defects, eye diseases, and/or limb hypoplasia. In rare cases, isolated manifestations in the brain or eye have been reported [15].

Antibodies against varicella zoster viruses (IgA, IgG, IgM) can be found in the serum of almost all subjects during and after a varicella infection. They can be verified by ELISA and IIFT. IgG- and IgM-antibodies against VZV are markers to confirm suspected VZV-infections, especially VZV-IgG-antibody titers during pregnancy [14, 16, 17, 18]. IgA-titers are typical for a re-infection (zoster) [19].



In addition to classic serodiagnosis of VZV, especially IgG and IgM antibodies suggestive of acute infection, measurement of VZV-IgG-avidity provides information making it possible to distinguish exactly between acute and chronic infection, as determination of avidity in other virus infections demonstrates [20]. Therefore it is of particular interest in pregnant women. Avidity describes the binding strength of specific antibody to antigen. It was found to be low in the first phase after primary infection but then to increase over time. Based on this additional information, repeated testing and unnecessary anxiety in patients can be avoided, which also is the case in the serological diagnostic of other virus infections [19, 20, 22, 23].

VZV myelitis or VZV encephalitis are diagnosed by the determination of antibodies against VZV in CSF and serum using ELISA [11]. CNS involvement results in the intrathecal synthesis of antibodies against VZV in cerebrospinal fluid (CSF). Due to the fact that specific antibodies can pass from the serum through the blood-brain barrier into the CSF by diffusion, a relative CSF/serum quotient (CSQrel., synonym: antibody specificity index) [20] is determined. The quotient is calculated from the amount of specific IgG antibodies in total CSF IgG in proportion to the amount of specific IgG antibodies in total serum IgG. During conversion the CSF/serum quotient of the pathogen-specific IgG-antibody concentrations CSQpath.-spec. (IgG) is put into relation to the CSF/serum quotient of the total IgG concentrations CSQtotal (IgG) [20]. A relative CSQ result above 1.5 indicates the production of specific antibodies in the CNS and the involvement of the CNS in the disease [24, 25, 26].

Generally, a life-long immunity develops, and this is also the case after a successful protective vaccination [17, 27, 28]. A passive immunisation with specific immunoglobulins is often given to immunocompromised seronegative people, such as tumour patients and recipients of transplants, as well as seronegative pregnant women after exposure to the virus [17, 29].

Literature references

1. Dueland AN. **Latency and reactivation of varicella zoster virus infections.** Scan J Infect Dis 100 (1996) 46-50.
2. Gilden D. **Varicella zoster virus and central nervous system syndromes.** Herpes 11 (2004) 89-94.
3. Cohrs RJ, Gilden DH, Mahalingam R. **Varicella zoster virus latency, neurological disease and experimental models: an update.** Front Biosci 9 (2004) 751-762.
4. Banz K, Wagenpfeil S, Neiss A, Hammerschmidt T, Wutzler P. **The burden of varicella in Germany. Potential risks and economic impact.** Eur J Health Econ 5 (2004) 46-53.
5. Heininger U, Baer G, Bonhoeffer J, Schaad UB. **Reliability of varicella history in children and adolescents.** Swiss Med Wkly 30 (2005) 252-255.
6. Sauerbrei A, Wutzler P. **Varicella during pregnancy. 1: Epidemiology and clinical aspects.** Dtsch Med Wochenschr 17 (2004) 1983-1986.
7. Kleinschmidt-DeMasters BK, Gilden DH. **Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates.** Arch Pathol Lab Med 125 (2001) 770-780.
8. Schaller B, Bernhard P, Graber P, Steck AJ. **Cerebellar syndrome after varicella infection without virus identification in cerebrospinal fluid – an important differential ataxia diagnosis.** [Article in German] Schweiz Rundsch Med Prax 88 (1999) 1901-1907.
9. Troya Garcia J, Espinosa de Los Monteros Garde MJ, Moreno B. **Varicella pneumonia in adult population: review of 21 cases.** [Article in Spanish] Rev Clin Esp 206 (2006) 566-569.
10. Volpi A, Gross G, Hercogova J, Johnson RW. **Current management of herpes zoster: the European view.** Am J Clin Dermatol 6 (2005) 317-325.
11. Gilden DH, Bennett JL, Kleinschmidt-DeMasters BK, Song DD, Yee AS, Steiner I. **The value of cerebrospinal fluid antiviral antibody in the diagnosis of neurologic disease produced by varicella zoster virus.** J Neur Sci 159 (1998) 140-144.

12. Sauerbrei A, Wutzler P. **Varicella during pregnancy. 2. Diagnosis, prevention and therapy.** Dtsch Med Wochenschr 24 (2004) 2045-2047.
13. Martin KA, Junker AK, Thomas EE, Van Allen MI, Friedmann JM. **Occurrence of Chickenpox during Pregnancy in Woman Seropositive for Varicella-Zoster Virus.** J Inf Dis 170 (1994) 991-995.
14. Zieger W, Friese K, Weigel M, Becker KP, Melchert F. **Varicella infection at birth.** Z Geburtshilfe Perinatol 198 (1994) 134-137.
15. Sauerbrei A, Pawlak J, Luger C, Wutzler P. **Intracerebral varicella-zoster virus reactivation in congenital varicella syndrome.** Dev Med Child Neurol 45 (2003) 837-840.
16. May G. **Serologische Diagnostik rekurrerender Varizellen-Zoster-Infektionen mit Hilfe des IgA-Antikörpernachweises.** Clin Lab 42 (1996) 761-764.
17. Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW. **Herpes zoster guideline of the German Dermatology Society (DDG).** J Clin Virol 26 (2003) 277-289. Discussion 291-293.
18. Sauerbrei A, Farber I, Brandstadt A, Schacke M, Wutzler P. **Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test.** J Virol Methods 119 (2004) 25-30.
19. RKI. **Infektionskrankheiten A bis Z.** (2006).
20. EUROIMMUN AG. Stöcker W, Schlumberger W. **Alle Beiträge zum Thema Autoimmundiagnostik.** In: Gressner A, Arndt T (Hrsg.) **Springer Lexikon Klinische Chemie. Medizinische Labordiagnostik von A-Z.** Springer Medizin Verlag, Heidelberg 1 (2007).
21. Kneitz RH, Schubert J, Tollmann F, Zens W, Hedman K, Weissbrich B. **A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid.** BMC Infect Dis 4 (2004) 33.
22. Levett PN, Sonnenberg* K, Sidaway F, Shead S, Niedrig M, Steinhagen* K, Horsman GB, Drebot MA (*EUROIMMUN AG). **Use of Immunoglobulin G Avidity Assays for Differentiation of Primary from Previous Infections with West Nile Virus.** Journal of Clinical Microbiology Vol 43 (2005) 5873-5875.
23. Levett PN, Sonnenberg* K, Shead S, Sidaway F, Niedrig M, Kreher* P, Arp* B, Erdmann* S, Jahn A, Steinhagen* K, Drebot M, Horsman GB (*EUROIMMUN AG). **IgG avidity determinations but not IgM tests are capable to differentiate recent from previous infections with West Nile Virus.** Poster zum 21. Annual clinical virology symposium and annual meeting Pan American society for clinical virology, USA, Florida, Clearwater beach (2005).
24. Reiber H, Peter JB. **Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.** J Neurol Sci 184 (2001) 101-122.
25. Reiber H, Lange P. **Virus-spezifische Antikörper in Liquor und Serum. ELISA-Analytik und Auswertung mittels Antikörper-Index und Quotientendiagramm.** Lab Med 15 (1991) 204-207.
26. Reiber H, Lange P. **Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain.** Clin Chem 37 (1991) 1153-1160.
27. Breuer J. **Live attenuated vaccine for the prevention of varicella-zoster virus infection: does it work, is it safe and do we really need it in the UK?** J Med Microbiol 52 (2003) 1-3.
28. Edmunds WJ, Brisson M. **The effect of vaccination on the epidemiology of varicella zoster virus.** J Infect 44 (2002) 211-9.
29. Kangro HO, Manzoor S, Harper DR. **Antibody Avidity Following Varicella-Zoster Virus Infections.** J Med Vir 33 (1991) 100-105.